Chengdu Shengnuo Biotech

Chengdu Shengnuo Biotech is a specialized biopharmaceutical company focused on the research, development, and large-scale manufacturing of peptide drugs. Based in Chengdu, China, the company provides a comprehensive range of products and services, including peptide APIs, finished drug products, and Contract Development and Manufacturing Organization (CDMO) services. Its core technological strength lies in its advanced peptide synthesis platforms, which utilize solid-phase, liquid-phase, and hybrid synthesis methods to produce complex sequences. The company's portfolio targets significant therapeutic areas such as metabolic diseases, osteoporosis, and cardiovascular health, featuring key products like Liraglutide and Teriparatide. Publicly listed on the Shanghai STAR Market, Chengdu Shengnuo Biotech serves a global clientele, supporting both generic drug development and innovative peptide research.